775545-30-7 Usage
General Description
3-Pyridinecarboxylic acid, 6-(hydroxymethyl)- (9CI) is a chemical compound that belongs to the pyridinecarboxylic acids group. It is characterized by the presence of a hydroxymethyl group attached to the sixth carbon of the pyridine ring. 3-Pyridinecarboxylic acid, 6-(hydroxymethyl)- (9CI) has been used in various pharmaceutical and chemical applications, including as a key intermediate in the synthesis of pharmaceuticals. It has also been studied for its potential biological and pharmacological properties. Due to its structure and functional groups, 3-Pyridinecarboxylic acid, 6-(hydroxymethyl)- (9CI) has the potential to exhibit diverse chemical and biological activities, making it a valuable compound for research and development in the fields of medicine and chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 775545-30-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,5,5,4 and 5 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 775545-30:
(8*7)+(7*7)+(6*5)+(5*5)+(4*4)+(3*5)+(2*3)+(1*0)=197
197 % 10 = 7
So 775545-30-7 is a valid CAS Registry Number.
775545-30-7Relevant articles and documents
OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT
-
, (2009/12/28)
An object of the present invention is to find a novel pharmacological effect of a compound having an HDAC inhibitory effect. The compound having an HDAC inhibitory effect of the invention has an excellent effect of cell morphological change on trabecular meshwork cells and/or effect of intraocular pressure reduction, and is therefore useful as a preventive and/or therapeutic agent for a disease considered to be associated with aqueous humor circulation and/or intraocular pressure, particularly as a preventive and/or therapeutic agent for glaucoma or ocular hypertension.
CYCLOALKYLAMINO ACID DERIVATIVES
-
Page/Page column 35, (2008/06/13)
The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
